Accompanied by Ren Xiaonan, Director of the Third Regional Inspection Office, and Dong Jihong, Deputy Director, as well as Jing Gang, Deputy Director of Zibo Market Supervision Bureau, Wu Shifu, Director of the Medical Devices Department of the Provincial Drug Administration, conducted an investigation at Qidu Pharma. Zheng Jiaqing, Zhang Jianyong, and Dong Xu, leaders of the group and the company, accompanied the visit.  

Wu Shifu and his delegation visited the group's pharmaceutical packaging industrial base, medical consumables and medical device production workshops, and the large-scale injection production project with an annual output of 1 billion bottles/bags. They gained a detailed understanding of the relevant industrial layout and the progress of key projects. He highly praised the company's practices and achievements, including extending the industrial chain to adjust and optimize the product structure, introducing advanced technology and equipment to lead industry upgrades, and adhering to industry-academia-research collaboration to continuously enhance innovation capabilities. He pointed out that the national "14th Five-Year Plan" for medical devices clearly states the need to "focus on the development of high-end medical equipment, smart healthcare, precision medicine, and other fields, and promote the medical device industry to move toward high-end, intelligent, and international development." Enterprises should closely follow the national strategic direction and accelerate the layout and development of the medical device sector. First, they should select the right development track, accelerate innovation in the field of diagnostic reagents, and focus on rapid diagnostic reagents, molecular diagnostic reagents, and immunodiagnostic reagents, especially products for early screening and precise diagnosis of major diseases and infectious diseases. Second, they should strengthen the integration of medicine and engineering, establish long-term cooperation mechanisms with medical institutions, universities, and research institutes, closely link clinical needs with technological innovation, and accelerate the transformation of medical devices from R&D to clinical application, promoting complementary development between the medical device and pharmaceutical industries.  

Zheng Jiaqing introduced the company's economic operations, technological innovation, and product structure adjustment, with a focus on the development status and future plans for medical devices, medical packaging materials, and medical consumables. He pointed out that the company will carefully study the national medical device development plan, focus on "bottleneck" technologies, emphasize import substitution, and achieve breakthroughs in full-range blood purification products, biological diagnostic reagent series, cell culture media series, and prefilled syringe series products. He emphasized that the company will continue to adhere to the dual approach of integrating industry-academia-research collaboration and independent R&D. On one hand, it will strengthen ties and cooperation with universities and research institutes, particularly deepening the "integration of medicine and engineering." On the other hand, it will strive to cultivate an independent R&D team, enhance independent innovation capabilities, and accelerate the development of the medical consumables and medical device sectors.  

During the symposium, the investigation team's leaders and experts engaged in in-depth discussions with company representatives on topics such as medical device regulatory policies, product lifecycle management, and innovation technology transformation. They also provided on-site answers to the company's questions regarding medical device-related policies.